Clinical Trial

Phase 1 Study of C.001 in Retinal Degeneration

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium. Participants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate three dose levels in a sequential manner. The primary objective is to assess the safety of C.001 over a 3-month period following administration. Participants will be followed for up to 12 months to further evaluate safety and explore changes in visual function and retinal structure.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-14.
Trial Details
NCT Number NCT07594236
Lead Sponsor Cellio Therapeutics Inc
Collaborators: California Institute for Regenerative Medicine (CIRM)
Conditions Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
Enrollment 15 participants
Start Date 2026-04-07
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10